Author:
McIntyre Roger S.,Necking Oscar,Schmidt Simon Nitschky,Reines Elin
Reference22 articles.
1. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study;Alam;Int. Clin. Psychopharmacol.,2014
2. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder;Baldwin;Curr. Med. Res. Opin.,2012
3. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?;Bandelow;J. Clin. Psychiatry,2006
4. Implications of the DSM’s emphasis on sadness and anhedonia in major depressive disorder;Buckner;Psychiatry Res.,2008
5. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder;Cao;Front. Psychol.,2019